Stockscreener 앱 받기
1.23
2.38%
-0.03
Biomea Fusion Inc 주식(BMEA)의 최신 뉴스
Biomea Fusion Inc (BMEA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomea Fusion Inc (BMEA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BMEA|Biomea Fusion Inc|Price:1.250|Chg%:-0.010 - TradingKey
Biomea Fusion Inc (BMEA) Balance Sheet - TradingKey
Biomea Fusion Inc (BMEA) Income Statement - TradingKey
Biomea Fusion Inc (BMEA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biomea Fusion Inc (BMEA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BMEA|Biomea Fusion Inc|Price:1.265|Chg%:+0.015 - TradingKey
Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biomea Fusion Inc (BMEA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomea Fusion Inc (BMEA) Institutional Confidence - TradingKey
Biomea Fusion Market Sentiment - Benzinga España
Biomea Fusion(BMEA) Stock Options Chain | Quotes & News - Moomoo
Biomea Fusion, Inc. Revenue Breakdown – NASDAQ:BMEA - TradingView
Biomea Fusion launches Phase II trial for icovamenib in type 1 diabetes - Traders Union
Biomea Fusion outlines key stages involved in clinical trials for new medicines - Traders Union
BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, - GuruFocus
Biomea Fusion presents Phase II data on icovamenib in type 1 diabetes at ADA meeting - Traders Union
Biomea Fusion Inc Financial Disclosures & SEC Filings - TradingView
Biomea Fusion Inc. (BMEA) Q1 2026 Earnings: Narrower-than-expected loss highlights cost managementDebt Analysis Report - dars.gov.et
Price to earnings forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Price to sales forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Price to book forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Enterprise value to revenue forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Insiders Buying Biomea Fusion Might Wish They Invested More, Stock Gains 12% - simplywall.st
Enterprise value to EBITDA forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Enterprise value to EBIT forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Biomea Fusion Inc Actuals & Estimates (NASDAQ:BMEA) - TradingView
COVALENT-112 Phase II data boost momentum for ico, Biomea Fusion pushes first-in-class strategy - Traders Union
BMEA Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Biomea Fusion forges new industry ties at BIO International Convention - Traders Union
Biomea Fusion Inc (BMEA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Team Fusion pinpoints this year leading trends at ADA2026 event - Traders Union
Number of shareholders of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Biomea Fusion Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineOne-Time Gain Impact - newsline.com
Biomea Fusion Inc. Q1 2026 Earnings: EPS Beat on Cost Discipline as Biotech Advances PipelinePost-Announcement Reaction - newsline.com
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan
Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price - Stock Titan
Biomea Fusion (BMEA) director Ray Sumita granted 196,299 stock options - Stock Titan
Biomea Fusion (BMEA) director receives 173,711-share stock option grant at $1.15 - Stock Titan
Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion | 4: Statement of changes in beneficial ownership of securities-Director Ray Sumita - Moomoo
Biomea Fusion (NASDAQ: BMEA) details 2026 director and auditor votes - Stock Titan
BMEA: Directors and auditors were approved by majority vote, with results to be filed with the SEC - TradingView
BMEA: All proposals, including director elections and auditor ratification, were approved - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion, Inc. (BMEA) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
BMEA Q1 2026 Earnings: EPS Beat on Controlled Spending Overshadowed by Pipeline ConcernsAnalyst Drop Coverage - newsline.com
Biomea Fusion unveils new icovamenib data showing durable insulin secretion gains in T1D and T2D - Traders Union
0.96%
0.92%
자본화:
|
볼륨(24시간):